Ribavirin (ICN-1229)

Catalog No.S2504 Batch:S250405

Print

Technical Data

Formula

C8H12N4O5
Molecular Weight 244.20864 CAS No. 36791-04-5
Solubility (25°C)* In vitro DMSO 48 mg/mL (196.55 mM)
Water 48 mg/mL (196.55 mM)
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
In vitro Ribavirin significantly reduces the efficiency with which progeny subgenomic replicons transfect new cells in the replicon system, although ribavirin has little effect on levels of HCV replication. Ribavirin increases the mutation frequency of HCV, with the highest rates of mutations being found in the NS5A-encoding region. Ribavirin enhances TH1 while inhibiting T 2 cytokine production by stimulated T cells. [1] Ribavirin shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. Ribavirin reduces infectious poliovirus production to as little as 0. 00001% in cell culture. [2] Ribavirin's antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. [3] Ribavirin markedly reduces viral-induced parameters of macrophage activation at physiologic concentrations (up to 500 mg/mL). Ribavirin inhibits the production of IL-4 by Th2 cells, whereas it does not diminish the production of IFN-gamma in Th1 cells. [4] Ribavirin exhibits antiviral activity against a broad range of both DNA and RNA viruses in vitro. Ribavirin is a cytostatic agent and causes a reduction in synthesis of DNA, RNA and proteins in exposed cells. Ribavirin is thought to induce a switch in T-helper cell phenotype from type 2 to type 1. [5]

Protocol (from reference)

References

  • https://pubmed.ncbi.nlm.nih.gov/16107837/
  • https://pubmed.ncbi.nlm.nih.gov/11100123/
  • https://pubmed.ncbi.nlm.nih.gov/11371613/
  • https://pubmed.ncbi.nlm.nih.gov/9531310/
  • https://pubmed.ncbi.nlm.nih.gov/16287208/

Customer Product Validation

<p>(E) Left panel, Western blot showed that 20 μM Ribavirin effectively inhibits elevated Sox2 expression in irradiated SW1990 cells. Right panel, qPCR analysis showed that Sox2 mRNA level in irradiated SW1990 cells at 48 hours was lower than that in non-irradiated SW1990 cells, *p < 0.05. (F) Left panel, Western blot showed 20 μM Ribavirin inhibits elevated Sox2 expression in irradiated BxPc-3 cells. Right panel, qPCR analysis showed that there is no significant fluctuation of Sox2 mRNA in irradiated BxPc-3 cells and Ribavirin did not influence sox2 mRNA level in irradiated BxPc-3 cells.</p>

, , Cancer Lett, 2016, 375(1):31-8.

Inhibition of viral replication and ensuing myocardial apoptosis ameliorates HDACI-exacerbated viral myocarditis. (A) CVB3-infected cardiac myocytes (MOI, 5) were treated with 1 μM SAHA and the indicated concentrations of ribavirin for 24 h. Cell extracts were analyzed by Western blotting with the indicated antibodies. (B) CVB3-infected cardiac myocytes (MOI, 5) were treated with 1 μM SAHA and 200 μg/ml ribavirin for 24 h. CVB3 titers in cell culture supernatants were determined by TCID50 assay (n = 4). (C) Cardiac myocytes were treated with 200 μg/ml ribavirin for 24 h. Cells morphology was examined by light microscope (scale bar, 100 μm). (D to F) CVB3-infected cardiac myocytes (MOI, 5) were treated with 2 μM SAHA in the presence or absence of 800 μg/ml ribavirin for 24 h. (D) Cell morphology was examined by light microscope (scale bar, 100 μm). (E and F) Cells were collected and stained with 7-AAD and FITC-labeled annexin V, followed by flow cytometric analysis (n = 3). (G and H) BALB/c mice were infected with CVB3 on day 0 and then simultaneously treated with SAHA (50 mg/kg) and ribavirin (100 mg/kg) or vehicle PBS daily from day 0 to day 7 p.i. (G) Survival rate was monitored daily until day 7 p.i. (n = 10). (H) Paraffin sections of heart tissues were prepared on day 7 p.i., and cardiac injury was revealed by H&E (scale bar, 50 μm). *, P < 0.05; ***, P < 0.001.

Data from [ , , J Virol, 2015, 89(20):10512-23. ]

Establishment of Vero-rBoDV-1-Gluc cells to monitor BoDV-1 replication. (A) Dose- and time-dependent inhibitory effects of ribavirin on BoDV-1 replication. Vero-rBoDV-1-Gluc cells were treated with 20 or 40 μM of ribavirin for the indicated periods, and the luciferase activity in the cell supernatant was measured. (B) Quantification of BoDV-1 RNAs in Vero-rBoDV-1-Gluc cells treated with 20 or 40 μM of ribavirin for 72 h. Values are expressed as the mean + S.E. from 3 biological replicates. *, p < 0.05; **, p < 0.01; ****, p < 0.001.

Data from [ , , Antiviral Res, 2017, 143:237-245 ]

Selleck's Ribavirin (ICN-1229) has been cited by 27 publications

Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups [ Cancer Cell, 2025, 43(4):776-796.e14] PubMed: 40185092
Scalable control of stem cell fate by riboswitch-regulated RNA viral vector without genomic integration [ Mol Ther, 2025, 33(3):1213-1225] PubMed: 39797398
Dietary nucleic acids promote oral tolerance through innate sensing pathways in mice [ Nat Commun, 2024, 15(1):9461] PubMed: 39487135
Gasdermin D licenses MHCII induction to maintain food tolerance in small intestine [ Cell, 2023, 186(14):3033-3048.e20] PubMed: 37327784
Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase [ Antimicrob Agents Chemother, 2023, 67(7):e0046223] PubMed: 37310224
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization [ Cell Rep Methods, 2023, 3(10):100599] PubMed: 37797618
An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA [ Nat Commun, 2022, 13(1):2079] PubMed: 35440123
Revisiting the Mongolian Gerbil Model for Hepatitis E Virus by Reverse Genetics [ Microbiol Spectr, 2022, e0219321] PubMed: 35230152
2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors [ Antiviral Res, 2021, 196:105209] PubMed: 34801588
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase [ Antiviral Res, 2021, S0166-3542(21)00068-1] PubMed: 33894278

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.